Azacitidine betapharm 25 mg/mL powder for suspension for injection

DRUG2 trials

Sponsors

Beigene Ltd., Janssen Cilag International

Conditions

Acute Myeloid LuekemiaMyeloid malignancies (acute myeloid leukemia (AML)myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.

Phase 1

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl‑2 Inhibitor BGB‑11417 in Patients With Myeloid Malignancies

RecruitingCTIS2023-508881-14-00

Beigene Ltd.myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN., Myeloid malignancies (acute myeloid leukemia (AML)

Start: 2022-03-21Target: 53Updated: 2025-10-31

Phase 3

A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy

RecruitingCTIS2024-520154-38-00

Janssen Cilag InternationalAcute Myeloid Luekemia

Start: 2025-07-29Target: 246Updated: 2025-10-17